Clinical Trials Browser

OTHER × Pancreatic Adenocarcinoma Metastatic × spartalizumab × Clear all

NCT06396637 2024-05-02

PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC

Phase 2 Recruiting

Gastrointestinal

Pancreatic Adenocarcinoma Metastatic